{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:27:55Z","timestamp":1790659675694,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13555-025-01601-0","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T03:38:00Z","timestamp":1763955480000},"page":"231-245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dual Targeted Therapy for Hidradenitis Suppurativa: A Narrative Review"],"prefix":"10.1007","volume":"16","author":[{"given":"Kenan","family":"Kherallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire S.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raveena","family":"Ghanshani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Charrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Y.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"5","key":"1601_CR1","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3390\/pharmaceutics15051351","volume":"15","author":"YC Tsai","year":"2023","unstructured":"Tsai YC, Hung CY, Tsai TF. Efficacy and safety of biologics and small molecules for moderate-to-severe hidradenitis suppurativa: a systematic review and network meta-analysis. Pharmaceutics. 2023;15(5):1351. https:\/\/doi.org\/10.3390\/pharmaceutics15051351.","journal-title":"Pharmaceutics"},{"issue":"2","key":"1601_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/bjd\/ljad345","volume":"190","author":"JG Krueger","year":"2024","unstructured":"Krueger JG, Frew J, Jemec GBE, et\u00a0al. Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape. Br J Dermatol. 2024;190(2):149\u201362. https:\/\/doi.org\/10.1093\/bjd\/ljad345.","journal-title":"Br J Dermatol"},{"key":"1601_CR3","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.2147\/CCID.S483871","volume":"17","author":"E Ames","year":"2024","unstructured":"Ames E, Sanders M, Jacobs M, Vida TA. Unlocking the mechanisms of hidradenitis suppurativa: inflammation and miRNA insights. Clin Cosmet Investig Dermatol. 2024;17:2829\u201346. https:\/\/doi.org\/10.2147\/CCID.S483871.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"1601_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","volume":"15","author":"F Seif","year":"2017","unstructured":"Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. 2017;15(1):23. https:\/\/doi.org\/10.1186\/s12964-017-0177-y.","journal-title":"Cell Commun Signal"},{"issue":"19","key":"1601_CR5","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139932","volume":"5","author":"MM Lowe","year":"2020","unstructured":"Lowe MM, Naik HB, Clancy S, et\u00a0al. Immunopathogenesis of hidradenitis suppurativa and response to anti\u2013TNF-\u03b1 therapy. JCI Insight. 2020;5(19):e139932. https:\/\/doi.org\/10.1172\/jci.insight.139932.","journal-title":"JCI Insight"},{"issue":"7","key":"1601_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103332","volume":"22","author":"L De Stefano","year":"2023","unstructured":"De Stefano L, Pallavicini FB, Mauric E, et\u00a0al. Tumor necrosis factor-\u03b1 inhibitor-related autoimmune disorders. Autoimmun Rev. 2023;22(7):103332. https:\/\/doi.org\/10.1016\/j.autrev.2023.103332.","journal-title":"Autoimmun Rev"},{"issue":"8","key":"1601_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/MCG.0000000000001583","volume":"55","author":"M Haider","year":"2021","unstructured":"Haider M, Lashner B. Dual targeted therapy for the management of inflammatory bowel disease. J Clin Gastroenterol. 2021;55(8):661\u20136. https:\/\/doi.org\/10.1097\/MCG.0000000000001583.","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"1601_CR8","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10494","volume":"14","author":"V Furer","year":"2023","unstructured":"Furer V, Elkayam O. Dual biologic therapy in patients with rheumatoid arthritis and psoriatic arthritis. Rambam Maimonides Med J. 2023;14(2):e0007. https:\/\/doi.org\/10.5041\/RMMJ.10494.","journal-title":"Rambam Maimonides Med J"},{"issue":"2","key":"1601_CR9","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.14617170","volume":"63","author":"PD Elizalde-Hern\u00e1ndez","year":"2025","unstructured":"Elizalde-Hern\u00e1ndez PD, Solis-Gonz\u00e1lez AJ, M\u00e9ndez-Flores FL, Estrada-Aguilar L. Hidradenitis suppurativa, report with dual therapy: small molecules and biological therapy. Rev Medica Inst Mex Seguro Soc. 2025;63(2):e6596. https:\/\/doi.org\/10.5281\/zenodo.14617170.","journal-title":"Rev Medica Inst Mex Seguro Soc"},{"key":"1601_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.08.002","author":"Z Islam","year":"2024","unstructured":"Islam Z, Ch\u2019en P, Choi S, Oprea Y, Campton K. The utility of upadacitinib to treat refractory hidradenitis suppurativa in an obese patient. JAAD Case Rep. 2024. https:\/\/doi.org\/10.1016\/j.jdcr.2024.08.002.","journal-title":"JAAD Case Rep."},{"issue":"3","key":"1601_CR11","first-page":"163; 164; 176","volume":"101","author":"HB Naik","year":"2018","unstructured":"Naik HB, McGinness A, Shinkai K. Concurrent anticytokine biologics for the management of severe hidradenitis suppurativa: are they safe and effective? Cutis. 2018;101(3):163; 164; 176.","journal-title":"Cutis"},{"issue":"5","key":"1601_CR12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3390\/cimb47050368","volume":"47","author":"A-M Matei-Man","year":"2025","unstructured":"Matei-Man A-M, Vesa \u0218C, Pu\u0219ca\u0219 AD, et\u00a0al. Assessment of TNF-\u03b1, IL-12\/23, and IL-17 in psoriasis: only TNF-\u03b1 reflects clinical response after 12 weeks of biologic treatment. Curr Issues Mol Biol. 2025;47(5):368.","journal-title":"Curr Issues Mol Biol"},{"issue":"11","key":"1601_CR13","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/art.40579","volume":"70","author":"PJ Mease","year":"2018","unstructured":"Mease PJ, Genovese MC, Weinblatt ME, et\u00a0al. Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17A-targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate. Arthritis Rheumatol. 2018;70(11):1778\u201389. https:\/\/doi.org\/10.1002\/art.40579.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"1601_CR14","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/art.40580","volume":"70","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Weinblatt ME, Aelion JA, et\u00a0al. ABT\u2010122, a bispecific dual variable domain immunoglobulin targeting tumor necrosis factor and interleukin\u201017A, in patients with rheumatoid arthritis with an inadequate response to methotrexate. Arthritis Rheumatol. 2018;70(11):1710\u201320. https:\/\/doi.org\/10.1002\/art.40580.","journal-title":"Arthritis Rheumatol"},{"key":"1601_CR15","doi-asserted-by":"publisher","first-page":"1283251","DOI":"10.3389\/fimmu.2023.1283251","volume":"14","author":"C Valero-Mart\u00ednez","year":"2023","unstructured":"Valero-Mart\u00ednez C, Urgelles JF, Sall\u00e9s M, et\u00a0al. Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain. Front Immunol. 2023;14:1283251. https:\/\/doi.org\/10.3389\/fimmu.2023.1283251.","journal-title":"Front Immunol"},{"issue":"4","key":"1601_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","volume":"8","author":"BG Feagan","year":"2023","unstructured":"Feagan BG, Sands BE, Sandborn WJ, et\u00a0al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023;8(4):307\u201320. https:\/\/doi.org\/10.1016\/S2468-1253(22)00427-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"1601_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/ibd\/izad064","volume":"30","author":"A Yerushalmy-Feler","year":"2024","unstructured":"Yerushalmy-Feler A, Olbjorn C, Kolho KL, et\u00a0al. Dual biologic or small molecule therapy in refractory pediatric inflammatory bowel disease (DOUBLE-PIBD): a multicenter study from the pediatric IBD Porto Group of ESPGHAN. Inflamm Bowel Dis. 2024;30(2):159\u201366. https:\/\/doi.org\/10.1093\/ibd\/izad064.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"1601_CR18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/jpn3.12179","volume":"79","author":"M Wlazlo","year":"2024","unstructured":"Wlazlo M, Meglicka M, Wiernicka A, Osiecki M, Matuszczyk M, Kierkus J. Combination biologic therapy in pediatric inflammatory bowel disease: safety and efficacy over a minimum 12-month follow-up period. J Pediatr Gastroenterol Nutr. 2024;79(1):54\u201361. https:\/\/doi.org\/10.1002\/jpn3.12179.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"1601_CR19","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/bjd.14270","volume":"174","author":"R Gniadecki","year":"2016","unstructured":"Gniadecki R, Bang B, Sand C. Combination of antitumour necrosis factor-\u03b1 and anti-interleukin-12\/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study. Br J Dermatol. 2016;174(5):1145\u20136. https:\/\/doi.org\/10.1111\/bjd.14270.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1601_CR20","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/art.20221","volume":"50","author":"MC Genovese","year":"2004","unstructured":"Genovese MC, Cohen S, Moreland L, et\u00a0al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004;50(5):1412\u20139. https:\/\/doi.org\/10.1002\/art.20221.","journal-title":"Arthritis Rheum"},{"key":"1601_CR21","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.2147\/JIR.S511309","volume":"18","author":"MJ Meng","year":"2025","unstructured":"Meng MJ, Kuo CJ, Lai MW, et\u00a0al. Advanced combination therapy with biologics and upadacitinib in refractory inflammatory bowel disease: a retrospective study from Taiwan. J Inflamm Res. 2025;18:2733\u201342. https:\/\/doi.org\/10.2147\/JIR.S511309.","journal-title":"J Inflamm Res"},{"key":"1601_CR22","doi-asserted-by":"publisher","first-page":"1074329","DOI":"10.3389\/fimmu.2022.1074329","volume":"13","author":"JW Chen","year":"2022","unstructured":"Chen JW, Zhang WS, Lin CS, Xu Q. Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis. Front Immunol. 2022;13:1074329. https:\/\/doi.org\/10.3389\/fimmu.2022.1074329.","journal-title":"Front Immunol"},{"issue":"5","key":"1601_CR23","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.jaad.2018.04.043","volume":"79","author":"A Ighani","year":"2018","unstructured":"Ighani A, Georgakopoulos JR, Shear NH, Walsh S, Yeung J. Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: a multicenter, retrospective study. J Am Acad Dermatol. 2018;79(5):953\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2018.04.043.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1601_CR24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/1203475416631328","volume":"20","author":"M AbuHilal","year":"2016","unstructured":"AbuHilal M, Walsh S, Shear N. Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study. J Cutan Med Surg. 2016;20(4):313\u20136. https:\/\/doi.org\/10.1177\/1203475416631328.","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"1601_CR25","doi-asserted-by":"publisher","first-page":"e626","DOI":"10.1097\/RHU.0000000000001767","volume":"28","author":"M Shurey","year":"2022","unstructured":"Shurey M, Yip A, Ziouzina O, Chan J, Dutz JP. Combination therapy with tofacitinib and IL-12\/23, IL-23, or IL-17A inhibition for the treatment of refractory psoriatic arthritis: a case series. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2022;28(2):e626\u20138. https:\/\/doi.org\/10.1097\/RHU.0000000000001767.","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"issue":"7","key":"1601_CR26","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1111\/ced.14000","volume":"44","author":"L Sacchelli","year":"2019","unstructured":"Sacchelli L, Patrizi A, Loi C, Bardazzi F. Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis. Clin Exp Dermatol. 2019;44(7):e243\u20134. https:\/\/doi.org\/10.1111\/ced.14000.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"1601_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4103\/ijd.IJD_548_18","volume":"64","author":"A De","year":"2019","unstructured":"De A, Das S, Dhoot D, Sarda A. Apremilast coadministered with secukinumab for safe and effective control of psoriasis with resultant reduction of maintenance dose of the biologic. Indian J Dermatol. 2019;64(3):239\u201341. https:\/\/doi.org\/10.4103\/ijd.IJD_548_18.","journal-title":"Indian J Dermatol"},{"issue":"2","key":"1601_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jdcr.2019.10.010","volume":"6","author":"KT Savage","year":"2020","unstructured":"Savage KT, Santillan MR, Flood KS, Charrow A, Porter ML, Kimball AB. Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. JAAD Case Rep. 2020;6(2):99\u2013102. https:\/\/doi.org\/10.1016\/j.jdcr.2019.10.010.","journal-title":"JAAD Case Rep"},{"key":"1601_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111435","volume":"127","author":"A Heidari","year":"2024","unstructured":"Heidari A, Ghane Y, Heidari N, Sadeghi S, Goodarzi A. A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for hidradenitis suppurativa treatment. Int Immunopharmacol. 2024;127:111435. https:\/\/doi.org\/10.1016\/j.intimp.2023.111435.","journal-title":"Int Immunopharmacol"},{"key":"1601_CR30","unstructured":"Incyte announces positive topline results from two phase 3 clinical trials of povorcitinib in patients with hidradenitis suppurativa | Incyte. https:\/\/investor.incyte.com\/news-releases\/news-release-details\/incyte-announces-positive-topline-results-two-phase-3-clinical\/. Accessed 16 Oct 2025."},{"key":"1601_CR31","unstructured":"AbbVie. A phase 3, randomized, placebo-controlled, double-blind study to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with moderate to severe hidradenitis suppurativa who have failed anti-TNF therapy. clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT05889182. Accessed 29 Oct 2025."},{"issue":"2","key":"1601_CR32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10620-023-08182-y","volume":"69","author":"Y Miyatani","year":"2024","unstructured":"Miyatani Y, Choi D, Choi NK, Rubin DT. Dual-targeted therapy with upadacitinib and ustekinumab in medically complex Crohn\u2019s disease. Dig Dis Sci. 2024;69(2):355\u20139. https:\/\/doi.org\/10.1007\/s10620-023-08182-y.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"1601_CR33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/ibd\/izab176","volume":"28","author":"SD Lee","year":"2022","unstructured":"Lee SD, Singla A, Harper J, et\u00a0al. Safety and efficacy of tofacitinib in combination with biologic therapy for refractory Crohn\u2019s disease. Inflamm Bowel Dis. 2022;28(2):309\u201313. https:\/\/doi.org\/10.1093\/ibd\/izab176.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"1601_CR34","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/ibd\/izab112","volume":"27","author":"QA Alayo","year":"2021","unstructured":"Alayo QA, Khatiwada A, Patel A, et\u00a0al. Effectiveness and safety of combining tofacitinib with a biologic in patients with refractory inflammatory bowel diseases. Inflamm Bowel Dis. 2021;27(10):1698\u2013702. https:\/\/doi.org\/10.1093\/ibd\/izab112.","journal-title":"Inflamm Bowel Dis"},{"key":"1601_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X251352160","volume":"13","author":"S Antolini","year":"2025","unstructured":"Antolini S, Scagliosi G, Veliaj O, Carletto A, Fracassi E, Gisondi P. A successful combination of upadacitinib and guselkumab in refractory psoriasis and psoriatic arthritis: a case report. SAGE Open Med Case Rep. 2025;13:2050313X251352160. https:\/\/doi.org\/10.1177\/2050313X251352160.","journal-title":"SAGE Open Med Case Rep"},{"key":"1601_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111586","volume":"129","author":"M Bekta\u015f","year":"2024","unstructured":"Bekta\u015f M, Ay M, Hamdi Uyar M, \u0130kbal K\u0131l\u0131\u00e7 M. Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: promising results from retrospective observational study. Int Immunopharmacol. 2024;129:111586. https:\/\/doi.org\/10.1016\/j.intimp.2024.111586.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"1601_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2024.100251","volume":"3","author":"V Burlakov","year":"2024","unstructured":"Burlakov V, Kozlova A, Pershin D, et\u00a0al. Combined therapy with IL-1 and JAK inhibitors in a patient with the NLRP1 gene mutation and a complex inflammatory phenotype. J Allergy Clin Immunol Glob. 2024;3(3):100251. https:\/\/doi.org\/10.1016\/j.jacig.2024.100251.","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"4","key":"1601_CR38","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et\u00a0al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1601_CR39","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y, et\u00a0al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450\u201361. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.006.","journal-title":"Gastroenterology"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01601-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01601-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01601-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:40:34Z","timestamp":1770190834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01601-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1601"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01601-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kenan Kherallah, Claire S. Chung, and Raveena Ghanshani have nothing to disclose. Alexandra Charrow is on the board of the HSF, has served on advisory boards for Novartis, BCG, Incyte, and Avalo. She is an investigator for studies with Sonoma, Incyte, Insmed, and Avalo. Julia M. Riley has served as an investigator for AbbVie, Novartis, Moonlike, and Incyte. Christopher J. Sayed has been a speaker for Abbvie, Novartis, and UCB, consultant for AbbVie, Novartis, UCB, Incyte, InflaRx, Astrazeneca, Alumis, Sonoma Biotherapeutics, Cantargia, Navigator Medicines, Elasmogen, Sanofi, Sandoz, Moonlake Therapeutics, and an investigator for Novartis, UCB, Incyte, InflaRx, Astrazeneca. Vivian Y. Shi is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF), an advisor for the National Eczema Association, is a stock shareholder of Learn Health and has served as an advisory board member, investigator, speaker, and\/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Genentech, Eli Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Dermavant, Apogee, MoonLake, Navigator Medicine, Boehringer Ingelheim, Almirall, Alumis, Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt\u2019s Bees, Galderma, Kiniksa, UCB, Ceraclere, Bain Capital, Target-PharmaSolutions, Castle Bioscience, Altus Lab\/cQuell, MYOR, Polyfins Technology, GpSkin and Skin Actives Scientific. Katrina H. Lee has served as an investigator or advisor for Novartis, Incyte. The other authors have no other conflicts to disclose. Jennifer L. Hsiao is on the board of directors for the HS Foundation, and has served as an advisor, investigator, and\/or speaker for AbbVie, Amgen, Aclaris, AstraZeneca, Boehringer Ingelheim, Galderma, Incyte, Moonlake, Navigator Medicines, Novartis, Pfizer, Sanofi, Regeneron, UCB. Jennifer L. Hsiao is an Editorial Board member of Dermatology and Therapy. Jennifer L. Hsiao was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This review is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}